Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus
Open Access
- 4 June 2012
- journal article
- review article
- Published by Hindawi Limited in International Journal of Rheumatology
- Vol. 2012, 1-11
- https://doi.org/10.1155/2012/718237
Abstract
Systemic lupus erythematosus (SLE) is a chronic, systemic, and autoimmune disease, whose etiology is still unknown. Although there has been progress in the treatment of SLE through the use of glucocorticoid and immunosuppressive drugs, these drugs have limited efficacy and pose significant risks of toxicity. Moreover, prognosis of patients with SLE has remained difficult to assess. TRIM21/Ro52/SS-A1, a 52-kDa protein, is an autoantigen recognized by antibodies in sera of patients with SLE and Sjögren's syndrome (SS), another systemic autoimmune disease, and anti-TRIM21 antibodies have been used as a diagnostic marker for decades. TRIM21 belongs to the tripartite motif-containing (TRIM) super family, which has been found to play important roles in innate and acquired immunity. Recently, TRIM21 has been shown to be involved in both physiological immune responses and pathological autoimmune processes. For example, TRIM21 ubiquitylates proteins of the interferon-regulatory factor (IRF) family and regulates type I interferon and proinflammatory cytokines. In this paper, we summarize molecular features of TRIM21 revealed so far and discuss its potential as an attractive therapeutic target for SLE.Keywords
Funding Information
- Japan Society for the Promotion of Science (23791118)
This publication has 119 references indexed in Scilit:
- Alloimmunization against RBC or PLT antigens is independent of TRIM21 expression in a murine modelMolecular Immunology, 2011
- Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPαOncogene, 2011
- Downregulation of active IKKβ by Ro52-mediated autophagyMolecular Immunology, 2010
- Cytoplasmic relocation of Daxx induced by Ro52 and FLASHHistochemistry and Cell Biology, 2010
- Pathogenesis of human systemic lupus erythematosus: recent advancesTrends in Molecular Medicine, 2010
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Dynamic movements of Ro52 cytoplasmic bodies along microtubulesHistochemistry and Cell Biology, 2009
- TRIM family proteins and their emerging roles in innate immunityNature Reviews Immunology, 2008
- Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein functionProceedings of the National Academy of Sciences of the United States of America, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004